Merck & Co. has completed a third successful Phase 3 trial of its oral PCSK9 inhibitor in hyperlipidemia, pushing the drug closer to regulatory approval. The CORALreef program results solidify the drug’s profile as an effective treatment for lowering LDL cholesterol across broader patient populations. This development aligns with Merck’s efforts to bring innovative lipid-lowering therapies to market, a space traditionally dominated by injectable biologics. The oral modality offers convenience and potential broader adoption among patients with elevated cholesterol.